Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CR6261 in H1N1 Influenza Healthy Human Challenge
NCT02371668Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2015
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of diridavumab in H1N1 influenza (H1N1), sponsored by National Institute of Allergy and Infectious Diseases. Started Feb 2015; status: completed.
02
Drugs
diridavumab
03
Conditions
H1N1 influenza (H1N1)
Beyond the preview
Go deeper on NCT02371668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02371668.